News Focus
News Focus
icon url

ThomasS

01/25/11 5:21 PM

#113230 RE: jbog #113228

MNTA: Nice miss, Jbog:

Momenta Pharma thesis unchanged on Teva news, says Cowen
Cowen continues to believe Momenta's M-Enoxaprin is worth mid $20's to shares and reiterates its Outperform rating